Intrexon-backed regenerative medicine company Histogenics went public after raising $89m in venture capital.
US-based regenerative medicine developer Histogenics has raised $65m from an initial public offering on Nasdaq, issuing 5.9 million shares priced at $11 each, below its $13-15 range.
Histogenics will use the proceeds to advance its lead product candidate, NeoCart, to Phase 3 clinical trials, to fund its partnership with life sciences company Intrexon around a synthetic biology technology platform and to increase its manufacturing capabilities for NeoCart.
Intrexon, which already held $10m of convertible promissory notes ahead of the flotation,…
